TABLE 2.
Treatment characteristics of patients on adalimumab
| Characteristic | Patients |
|
|---|---|---|
| n | (%) | |
| Duration of treatment | ||
| Mean (years) | 2.6 | |
| Range | 27 days to 6.2 years | |
| Therapy during adalimumab treatment | ||
| Topical corticosteroids | 20 | 62.5 |
| Oral corticosteroids | 7 | 21.9 |
| Corticosteroids (any route) | 23 | 71.9 |
| IMT | ||
| 1 IMT | 15 | 46.9 |
| 2 IMT | 5 | 15.6 |
| ≥3 IMT | 2 | 6.3 |
| Discontinued adalimumab | 13 | 40.6 |
| Reason discontinued | ||
| Ineffectiveness | 4 | 30.8 |
| Other | 8 | 61.5 |
| Unknown | 1 | 7.7 |
IMT, immunomodulatory therapy. ‘Other’ reasons for discontinuation were one each of: skin reaction, rash, fatigue and body ache, angina, swelling of rectus muscles, retinal detachment, insurance carrier non-approval, and death from unknown cause.